Table 2. Peak nevirapine concentration is consistent with better adherence and viral load suppression.
| Grouping variable | cNVP in ng/ml, post-dosing at | |||
|---|---|---|---|---|
| 1 hour | 4 hours | 24 hours | ||
| Adherence | Good | 3391.72 | 3343.86 | 1872.36 |
| Fair | 3368.36 | 3433.21 | 2356.75 | |
| Poor | 1277.75 | 1637.68 | 2356.75 | |
| p value¶ | 0.002 | 0.009 | 0.788 | |
| CPS activity | Active (++) | 3983.01 | 3374.63 | 1234.62 |
| Occasional (+) | 2163.47 | 2884.92 | 3028.17 | |
| None (-) | 2147.67 | 2526.00 | 6168.36 | |
| p value¶ | 0.078 | 0.384 | 0.123 | |
| Virologic response | ART failure (25) | 2164.90 | 1660.47 | 5056.10 |
| ART responsive (33) | 3404.48 | 3899.75 | 2103.89 | |
| p value¶ | 0.004 | <0.001 | 0.972 | |
| Gender | Males | 2058.38 | 3259.43 | 6319.89 |
| Females | 3322.97 | 2807.04 | 1764.91 | |
| p value¶ | 0.657 | 0.192 | 0.108 | |
| Age group (years) | ≤25 | 2604.80 | 3828.60 | 5315.15 |
| 26–45 | 2424.83 | 3383.73 | 4431.59 | |
| >45 | 3666.36 | 2160.87 | 1292.83 | |
| p value¶ | 0.642 | 0.495 | 0.107 | |
| Regimen arm‡ | AZT | 1496.07 | 2878.39 | 5985.37 |
| D4T | 2280.63 | 2042.53 | 2075.74 | |
| TDF | 4691.05 | 3780.65 | 1834.04 | |
| p value¶ | 0.042 | 0.56 | 0.910 | |
¶Anova p value compares mean log10 plasma nevirapine concentrations (cNVP) between grouping variables. CPS, community peer-to-peer support.
‡Regimen arm includes 3TC+NVP in the ART backbone